Long-lasting partial regression of glioblastoma multiforme achieved by edotecarin: case report.
Year: 2006
Type: article
Study design: Case Report
Abstract: We describe the response to a new chemotherapy agent, topoisomerase I inhibitor edotecarin in an 18-year-old woman with recurring glioblastoma. The therapy was administered for 17 months. The radiological partial response and clinical improvement have been achieved, with minor toxicity. Median survival of patients with glioblastoma is 10 months. With edotecarin we have achieved promising result, which should encourage further investigations to develop more efficient therapy for such a deadly disease.
Source: PubMed
Institutions: Klinički Bolnički Centar Split, University of Split
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2101486077